Weight gain as a complication of intensification of glucose control with automated insulin delivery systems.
Julia Kelly, Devin Steenkamp, Elizabeth Brouillard, Howard Wolpert
Author Information
- Julia Kelly: Section of Endocrinology, Diabetes, Nutrition, & Weight Management, Chobanian and Avedisian School of Medicine, Boston University and Boston Medical Center, Boston, Massachusetts, USA.
- Devin Steenkamp: Section of Endocrinology, Diabetes, Nutrition, & Weight Management, Chobanian and Avedisian School of Medicine, Boston University and Boston Medical Center, Boston, Massachusetts, USA.
- Elizabeth Brouillard: Section of Endocrinology, Diabetes, Nutrition, & Weight Management, Chobanian and Avedisian School of Medicine, Boston University and Boston Medical Center, Boston, Massachusetts, USA.
- Howard Wolpert: Section of Endocrinology, Diabetes, Nutrition, & Weight Management, Chobanian and Avedisian School of Medicine, Boston University and Boston Medical Center, Boston, Massachusetts, USA.
No abstract text available.
- Corbin KD, Driscoll KA, Pratley RE, et al. Obesity in type 1 diabetes: pathophysiology, clinical impact, and mechanisms. Endocr Rev. 2018;39:629‐663.
- The DCCT Research Group. Weight gain associated with intensive therapy in the diabetes control and complications trial. Diabetes Care. 1988;11:567‐573.
- Brown SA, Kovatchev BP, Raghinaru D, et al. Six‐month randomized, multicenter trial of closed‐loop control in type 1 diabetes. N Engl J Med. 2019;381:1707‐1717.
- Brown SA, Forlenza GP, Bode BW, et al. Multicenter trial of a tubeless, on‐body automated insulin delivery system with customizable glycemic targets in pediatric and adult participants with type 1 diabetes. Diabetes Care. 2021;44:1630‐1640.
- Bionic Pancreas Research Group. Multicenter, randomized trial of a bionic pancreas in type 1 diabetes. N Engl J Med. 2022;387:1161‐1172.
- Tauschmann M, Thabit H, Bally L, et al. Closed‐loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12‐week randomised trial. Lancet. 2018;392:1321‐1329.
- Steenkamp D, Brouillard E, Aia C, et al. Reducing inequity in the use of automated insulin delivery systems by adults with type 1 diabetes: key learnings from a safety net diabetes clinic program. Endocr Pract. 2024;30:558‐563.
- Akturk HK, Snell‐Bergeon J, Shah VN. Efficacy and safety of tandem control IQ without user‐initiated boluses in adults with uncontrolled type 1 diabetes. Diabetes Technol Ther. 2024;24:779‐783.
- SECURE‐T2D Study Consortium. Glycemic improvement with use of the omnipod 5 automated insulin delivery system in adults with type 2 diabetes—results of the SECURE‐T2D pivotal trial. Diabetes. 2024;73(suppl. 1):1904‐LB.
- Pinsker JE, Bartee A, Katz M, et al. Predictive low‐glucose suspend necessitates less carbohydrate supplementation to rescue hypoglycemia: need to revisit current hypoglycemia treatment guidelines. Diabetes Technol Ther. 2021;23:512‐516.
- /This work received no external funding.
